Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN) Head-To-Head Contrast

Kiora Pharmaceuticals (NASDAQ:KPRX) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Institutional and Insider Ownership

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 0.1% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Kiora Pharmaceuticals and Stevanato Group”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02 million	0.52	$3.60 million	($2.09)	-1.08
Stevanato Group	$1.19 billion	3.89	$127.45 million	€0.57	26.89

Stevanato Group has higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kiora Pharmaceuticals has a beta of -0.82, indicating that its stock price is 182% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Profitability

This table compares Kiora Pharmaceuticals and Stevanato Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-36.35%	-25.82%
Stevanato Group	11.99%	10.52%	6.32%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Kiora Pharmaceuticals and Stevanato Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1	1	1	0	2.00
Stevanato Group	0	3	1	1	2.60

Kiora Pharmaceuticals presently has a consensus target price of $10.00, suggesting a potential upside of 344.44%. Given Kiora Pharmaceuticals’ higher possible upside, equities analysts plainly believe Kiora Pharmaceuticals is more favorable than Stevanato Group.

Summary

Stevanato Group beats Kiora Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.